News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals Incorporated’s Board of Directors
July 8, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D. and Dennis Winger joined its board of directors.
Twitter
LinkedIn
Facebook
Email
Print
People
Vertex Pharmaceuticals
MORE ON THIS TOPIC
Deals
Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
November 5, 2026
·
2 min read
·
Gabrielle Masson
Mergers & acquisitions
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
November 5, 2026
·
2 min read
·
Annalee Armstrong
Deals
Boehringer bets big on China, offering $7B biobucks for Sino cancer programs
November 4, 2026
·
1 min read
·
Gabrielle Masson
Deals
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
November 4, 2026
·
2 min read
·
Gabrielle Masson